Overview

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
In this pilot study, the investigators would examine the safety and efficacy of integrase inhibitor-Raltegravir in the control of HIV/HBV co-infection.
Phase:
N/A
Details
Lead Sponsor:
Yunnan AIDS Care Center
Treatments:
Efavirenz
Lamivudine
Raltegravir Potassium
Tenofovir